Comparison guide

Ayahuasca vs Psilocybin

Two classic serotonergic psychedelics, compared on safety, legality, and the experience — including ayahuasca's serious MAOI drug interaction.

Comparing ayahuasca vs psilocybin comes down to a few real questions: what is legal where you live, how your medications interact, and what kind of experience you want. Both are classic serotonergic psychedelics studied for depression and trauma. But they differ sharply in safety, access, and ritual. This guide on ayahuasca vs mushrooms compares them side by side so you can see which fits your situation today.

Quick answer: ayahuasca vs psilocybin

Psilocybin is the option more people can legally access today. It has regulated centers in Oregon and Colorado and stronger trial data. Ayahuasca offers a longer, more ceremonial experience rooted in Amazonian tradition. But it is legal in the US only through religious exemptions, so most people travel abroad. Ayahuasca also carries a serious MAOI drug interaction that psilocybin does not.

For most people, the choice is shaped by two things first: your current medications and where you can legally go. We cover both in detail below.

Ayahuasca vs psilocybin: side-by-side comparison

FactorAyahuascaPsilocybin
Active compound N,N-DMT plus harmala MAOIs (harmine, harmaline) from the B. caapi vine. Psilocybin, which the body turns into psilocin, a 5-HT2A agonist.
Duration of experience About 4–6 hours, often with vomiting ("la purga") and diarrhea. About 4–6 hours, usually with less physical purging.
Legal status / access (US) Schedule I. Legal only via 4 religious exemptions; most access is at retreats abroad. Schedule I federally. Regulated legal access in Oregon and Colorado.
What it is studied for Depression, PTSD, and addiction in small, mostly early studies. Treatment-resistant depression, anxiety, and addiction in larger trials.
Evidence strength Promising but limited; few randomized controlled trials. Stronger; FDA Breakthrough Therapy status and Phase 3 results.
Safety / contraindications MAOI raises serotonin syndrome risk with SSRIs/SNRIs; cardiac and blood-pressure cautions. SSRIs may blunt effects; psychosis history is the main contraindication.
Setting Ceremony led by a shaman or facilitator, often over several nights. Clinical or licensed service-center session with a trained facilitator.

How ayahuasca and psilocybin work

Both drugs act on the brain's serotonin system. Psilocybin converts to psilocin, which switches on the 5-HT2A receptor. This makes the brain more flexible and can bring deep emotional or mystical experiences. Our full psilocybin guide covers the science in depth.

Ayahuasca is more complex because it is really two medicines combined. The brew mixes a DMT-containing plant with the Banisteriopsis caapi vine. DMT alone would be destroyed in your stomach. The vine contains MAOIs that block that breakdown, so the DMT can reach your brain. Our ayahuasca guide explains this pairing in detail.

That MAOI is the key difference. It makes ayahuasca work by mouth, but it also changes how your whole body handles serotonin. This matters a lot for safety, which we cover next.

Which feels more intense?

Many people find ayahuasca more physically demanding. The brew often causes strong vomiting and intense visions. Psilocybin can feel just as deep emotionally but is usually gentler on the body. Neither is "stronger" in a simple way. The right fit depends on what you can handle and want.

Safety and drug interactions

Drug interaction: The MAOI in ayahuasca can cause serotonin syndrome when mixed with SSRIs, SNRIs, other MAOIs, or many other serotonergic drugs. This reaction can be fatal. Reputable retreats require tapering off these medications under medical guidance, often for weeks beforehand. Never stop a prescribed antidepressant on your own. Psilocybin does not carry this MAOI interaction, though SSRIs can blunt its effects.3

Ayahuasca's MAOI also reacts with certain foods and stimulants, and it can raise blood pressure. People with heart conditions face added risk. A 2024 Florida jury awarded $15 million after a ceremony death tied to such risks, a reminder that screening is not optional.4

Psilocybin has a cleaner interaction profile but is not risk-free. The main concern is a personal or family history of psychosis. Both drugs can also bring up hard emotions during the session. For either path, careful screening lowers your risk a lot. Our psychedelic medication safety guide breaks down which drugs to avoid.

What the evidence shows

Ayahuasca vs psilocybin for depression

Both show promise for depression, but the evidence is not equal. A small 2019 randomized trial found ayahuasca improved treatment-resistant depression versus placebo.5 The study was tiny, and large trials are still missing.

Psilocybin's data is broader. In 2025, COMPASS Pathways reported that its Phase 3 trial of COMP360 psilocybin hit its primary endpoint for treatment-resistant depression.6 Psilocybin also holds FDA Breakthrough Therapy status. So for depression, psilocybin has the stronger formal evidence today.

Important: Neither drug is a guaranteed fix. Trial results describe averages, not promises. Both work best with proper screening, supervision, and follow-up care. Always talk to a licensed clinician before starting any treatment.

Both compounds are Schedule I at the federal level. But access looks very different in practice. Psilocybin has legal, regulated access through licensed service centers in Oregon (Measure 109) and Colorado (Proposition 122).7 You can book a session there if you meet the rules.

Ayahuasca has no such regulated program. Its only legal US path is through religious exemptions granted under the Religious Freedom Restoration Act. Four groups hold confirmed federal exemptions, including the União do Vegetal and Santo Daime.1 Outside those churches, most people travel to retreats in Peru, Costa Rica, or the Netherlands.

To see how your state treats each drug, check our guide on what psychedelics are legal in the US. If you are considering travel for either experience, our find a retreat tool can help you compare vetted options.

Aftercare and integration

The session is only half the work. What you do afterward shapes the lasting benefit. Both ayahuasca and psilocybin can surface strong emotions and memories. Talking those through with a trained guide helps you make sense of them.

This follow-up work is called integration. Our integration therapy guide explains how it works and why it matters for both substances. Good preparation and good aftercare improve results no matter which you choose.

The verdict: ayahuasca vs psilocybin — which to pick when

Choose psilocybin if you take an SSRI or SNRI and cannot safely stop it, want legal access without leaving the country, prefer a gentler physical experience, or want the option backed by stronger trial data. For most US residents, psilocybin is the more accessible and lower-risk starting point.

Choose ayahuasca if you are drawn to a traditional ceremony, can fully taper off interacting medications under medical care, are willing to travel to a reputable retreat abroad, and want a longer, ritual-based experience. The MAOI interaction makes careful screening essential here.

Still unsure which substance matches your goals and health history? Take our which psychedelic quiz for a personalized starting point, or use our find a retreat tool to compare safe, vetted options.

Frequently asked questions

Is ayahuasca stronger than mushrooms?

Many people find ayahuasca more physically intense. It often causes heavy vomiting and vivid visions over 4 to 6 hours. Psilocybin mushrooms can feel just as deep emotionally but are usually gentler on the body. 'Stronger' depends on dose, setting, and the person, so neither is simply more powerful than the other.

Which is better for depression, ayahuasca or psilocybin?

Both show promise, but psilocybin has stronger formal evidence today. It holds FDA Breakthrough Therapy status and has Phase 3 trial results for treatment-resistant depression. Ayahuasca has one small positive randomized trial but lacks large studies. For most people, psilocybin is the better-supported and more accessible choice for depression right now.

Which is safer, ayahuasca or psilocybin?

Psilocybin has a cleaner safety profile for most people. Ayahuasca contains an MAOI that can cause serotonin syndrome when mixed with SSRIs, SNRIs, or other serotonergic drugs, which can be fatal. It also carries food and cardiac cautions. Both require screening, but ayahuasca's drug interactions make careful medical preparation essential.

Where can I legally do ayahuasca or psilocybin?

Psilocybin has regulated legal access at licensed service centers in Oregon and Colorado. Ayahuasca is legal in the US only through four recognized religious exemptions, such as the União do Vegetal and Santo Daime. Outside those churches, most people travel to retreats in Peru, Costa Rica, or the Netherlands.

Get psychedelic research & policy updates

New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.

Free. No spam. Unsubscribe anytime.

← Back to all therapy guides

Sources

  1. US Drug Enforcement Administration. Controlled Substances Act schedules (DMT and psilocybin, Schedule I). DEA Diversion Control Division, 2024. DEA.
  2. Supreme Court of the United States. Gonzales v. O Centro Espírita Beneficente União do Vegetal (RFRA religious exemption for ayahuasca). 546 U.S. 418, 2006. Justia.
  3. Malcolm BJ, Lee KC. Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness? (MAOI and serotonin syndrome risk). Mental Health Clinician, 2017. PubMed.
  4. Associated Press. Florida jury awards $15 million over ayahuasca ceremony death at Soul Quest. AP News, 2024. AP News.
  5. Palhano-Fontes F, Barreto D, Onias H, et al.. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine, 2019. PubMed.
  6. Compass Pathways. Compass Pathways achieves primary endpoint in Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression. Compass Pathways investor news, 2025. Compass Pathways.
  7. Oregon Health Authority. Oregon Psilocybin Services (Measure 109) program overview. Oregon.gov, 2024. Oregon.gov.